‌

US Patent 11932624 MDM2 degraders and uses thereof

Patent 11932624 was granted and assigned to Kymera Therapeutics on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Kymera Therapeutics

0

Current Assignee

Kymera Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Nan Ji0

Xiaozhang Zheng0

Xiao Zhu0

Matthew M. Weiss0

Date of Patent

March 19, 2024

0

Patent Application Number

179630320

Date Filed

October 10, 2022

0

Patent Citations

US Patent 7074620 Controlling protein levels in eucaryotic organisms

0

US Patent 7083983 Inhibitors of the interaction between P53 and MDM2

0

US Patent 7132421 CIS-imidazoles

0

US Patent 7173015 Inhibition of Syk kinase expression

0

US Patent 7208157 Proteolysis targeting chimeric pharmaceutical

0

US Patent 6916833 Substituted piperidines

0

US Patent 6949537 PI-3 kinase inhibitor prodrugs

0

US Patent 7041298 Proteolysis targeting chimeric pharmaceutical

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11932624 MDM2 degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.